HC Wainwright Has Bearish Outlook for CADL FY2028 Earnings

Candel Therapeutics, Inc. (NASDAQ:CADL) – Investment analysts at HC Wainwright lowered their FY2028 earnings estimates for Candel Therapeutics in a research note issued on Thursday, August 13th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of $0.69 for the year, down from their prior estimate of $0.71. HC Wainwright has a “Buy” rating and a $23.00 price target on the stock. The consensus estimate for Candel Therapeutics’ current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for Candel Therapeutics’ FY2029 earnings at $1.41 EPS.

Several other equities research analysts also recently commented on CADL. Cantor Fitzgerald began coverage on Candel Therapeutics in a report on Monday, April 20th. They issued an “overweight” rating for the company. Stifel Nicolaus started coverage on shares of Candel Therapeutics in a research note on Monday, July 13th. They set a “buy” rating and a $22.00 price objective on the stock. Wall Street Zen upgraded Candel Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Candel Therapeutics in a research note on Friday, July 17th. Finally, Zacks Research upgraded Candel Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. Seven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Candel Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $18.57.

Candel Therapeutics Stock Performance

CADL opened at $11.80 on Friday. The business’s 50-day simple moving average is $9.62 and its 200 day simple moving average is $7.37. Candel Therapeutics has a 52-week low of $4.35 and a 52-week high of $11.87. The company has a debt-to-equity ratio of 0.34, a quick ratio of 28.05 and a current ratio of 28.05. The firm has a market capitalization of $864.59 million, a PE ratio of -12.04 and a beta of -0.51.

Candel Therapeutics (NASDAQ:CADL) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.25).

Insiders Place Their Bets

In other Candel Therapeutics news, insider Francesca Barone sold 23,447 shares of Candel Therapeutics stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $10.06, for a total value of $235,876.82. Following the completion of the sale, the insider owned 77,362 shares in the company, valued at $778,261.72. The trade was a 23.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CTO Seshu Tyagarajan sold 7,000 shares of the stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $10.02, for a total transaction of $70,140.00. Following the transaction, the chief technology officer owned 83,865 shares in the company, valued at approximately $840,327.30. The trade was a 7.70% decrease in their position. The disclosure for this sale is available in the SEC filing. 14.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Candel Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC bought a new stake in shares of Candel Therapeutics during the 1st quarter valued at $845,000. Halter Ferguson Financial Inc. increased its position in shares of Candel Therapeutics by 20.9% in the first quarter. Halter Ferguson Financial Inc. now owns 904,051 shares of the company’s stock worth $4,430,000 after purchasing an additional 155,996 shares during the period. Walleye Capital LLC acquired a new position in Candel Therapeutics in the second quarter valued at about $419,000. Renaissance Technologies LLC bought a new stake in Candel Therapeutics during the first quarter worth about $63,000. Finally, AlphaCentric Advisors LLC bought a new stake in Candel Therapeutics during the first quarter worth about $178,000. 13.93% of the stock is owned by institutional investors and hedge funds.

Candel Therapeutics Company Profile

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.